Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5C70M)

• Drug Name: T-607 Drug Info
• Synonyms: T-607; AC1LA5AL; 2-[(Ethyl)disulfanyl]-2-methylthioacetamide; 2-(ethyldisulfanyl)-2-methylsulfanylacetamide; 2-(ethyldisulfanyl)-2-methylsulfanyl-acetamide; 92504-EP2298748A2; 92504-EP2295416A2

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 462014
  TTD Drug ID: DM5C70M

Molecule-Related Drug Atlas

Drug(s) Targeting Tubulin beta (TUBB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vincristine	DMINOX3	Acute lymphoblastic leukaemia	2A85	Approved	[3]
Albendazole	DMYZ57N	Echinococcus granulosus infectious disease		Approved	[4]
Vindesine	DMVR628	Acute lymphoblastic leukaemia	2A85	Approved	[5]
Taxol	DMUOT9V	Breast cancer	2C60-2C65	Approved	[6]
Mebendazole	DMO14SG	Ascariasis	1F62	Approved	[4]
Plinabulin	DMD7L48	Non-small-cell lung cancer	2C25.Y	Phase 3	[7]
Batabulin	DMHWE5R	Solid tumour/cancer	2A00-2F9Z	Phase 2/3	[8]
ABT-751	DMNG35S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
DOLASTATIN-10	DMDUV1S	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]
BNC-105	DMJC8DR	Mesothelioma	2C51.2	Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tubulin beta (TUBB)	TTYFKSZ	NOUNIPROTAC	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT00054249) T900607 in Treating Patients With Gastroesophageal Junction Cancer. U.S. National Institutes of Health.
• [2] Nucleophilic reactions of N-ethoxycarbonyliminopyridinium ylide with alpha,beta-unsaturated carbonyl compounds. Volume 28, Issue 6, 1972, Pages 1469-1476.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Flubendazole interferes with a wide spectrum of cell homeostatic mechanisms in Echinococcus granulosus protoscoleces. Parasitol Int. 2009 Sep;58(3):270-7.
• [5] Antiproliferating activity of the mitotic inhibitor pironetin against vindesine- and paclitaxel-resistant human small cell lung cancer H69 cells. Anticancer Res. 2007 Mar-Apr;27(2):729-36.
• [6] Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
• [7] NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs. 2006 Jan;17(1):25-31.
• [8] Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier. J Med Chem. 2001 Oct 25;44(22):3599-605.
• [9] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [10] Total synthesis and biological evaluation of ustiloxin natural products and two analogs. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4804-7.
• [11] The vascular disrupting agent BNC105 potentiates the efficacy of VEGF and mTOR inhibitors in renal and breast cancer.Cancer Biol Ther.2014;15(11):1552-60.